Eliem Therapeutics Inc
Research Eliem Therapeutics Inc (CLYM) on Bullrun: market cap USD 1.02B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCLYM
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.02B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 13.50M
- Free cash flow-USD 10.81M
Valuation Snapshot
latest market cap is USD 1.02B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 59.85M | -USD 54.54M | n/a | -0.88 | USD 35.69M | USD 541.00K | USD 160.48M |
| FY2024 | USD 0 | -USD 73.90M | -USD 15.56M | n/a | -1.53 | USD 87.23M | USD 532.00K | USD 211.88M |
| FY2023 | n/a | -USD 35.12M | -USD 20.60M | n/a | -1.3 | USD 93.11M | USD 349.00K | USD 107.60M |
| FY2022 | n/a | -USD 45.24M | n/a | n/a | -1.72 | USD 43.59M | n/a | USD 128.72M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.02B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 191.07M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 121.06M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 74.45M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 97.50M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 274.42M | n/a | n/a | n/a |
About Eliem Therapeutics Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Eliem Therapeutics Inc's market cap?
Eliem Therapeutics Inc's market capitalization is USD 1.02B.
What does Eliem Therapeutics Inc do?
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus.